オメガ3脂肪酸 ： 休止期脱毛症
B エビデンス 少なくとも1件のランダム化試験がこれを支持しており、おおむね一貫した結果が得られています。合計317名の参加者を対象とした11件の研究に基づく。11件中8件の研究で肯定的な効果が示されている。
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'haircited.com';
const params = 'ingredient\u003Domega\u002D3\u0026condition\u003Dtelogen\u002Deffluvium';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
結論
Moderate evidence suggests that omega-3 fatty acids may help support hair recovery in telogen effluvium, though the research base is limited and they are usually studied alongside other nutrients.
- 8 out of 11 studies show positive effects, but total sample size is small (317 participants)
- Often studied as part of multi-nutrient supplement formulations
- No large-scale RCTs specifically for omega-3 and telogen effluvium
- May support recovery through anti-inflammatory and nutritional mechanisms
Key Study Findings
review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5
vs: Placebo
効果: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2%
None
narrative review
Herbal Remedies for Hair Loss: A Review of Efficacy and Safety.
Dose: varies by remedy and study
vs: Placebo
効果: None
None
scoping_review
n=16
A Scoping Review of Exosome Delivery Applications in Hair Loss.
Dose: variable; exosomes predominantly from mesenchymal stem cells (MSCs)
vs: Placebo
効果: None
None
review
The Use of Light-Based Therapies in the Treatment of Alopecia.
Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri
vs: Placebo
効果: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo
None
Cohort
n=200
Open-label
Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life …
Dose: high dose elemental iron (dose unspecified)
vs: Placebo
効果: Patients with baseline ferritin ≥50 ng/ml mostly 'very satisfied'; patients with ferritin <50 ng/ml
None
clinical trial (open-label)
Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with …
Dose: None
vs: Placebo
効果: None
None
Key Statistics
11
研究数
317
参加者数
↑
Positive
B
グレード
Referenced Papers
American journal of …
2026
1 件の引用
Cureus
2025
7 件の引用
Skin appendage disorders
2025
7 件の引用
Journal of cosmetic …
2025
Indian journal of …
2024
4 件の引用
Journal of cosmetic …
2023
6 件の引用
Journal of cosmetic …
2022
30 件の引用
NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India.
Observational
Journal of cosmetic …
2019
25 件の引用
Acta dermatovenerologica Croatica …
2016
6 件の引用
Georgian medical news
2007
Therapeutische Umschau. Revue …
2002
4 件の引用
Dermatologic clinics
1993
38 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 250-500 mg EPA+DHA/day
- hairloss:
- 1,000-2,000 mg/day
上限量： 3,000 mg/day EPA+DHA
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 | -- | Positive | -- |
| varies by remedy and study | -- | Positive | -- |
| variable; exosomes predominantly from mesenchymal stem cells (MSCs) | -- | Positive | 16 |
| Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri | -- | Positive | -- |
| high dose elemental iron (dose unspecified) | -- | Positive | 200 |
| None | -- | Positive | -- |
| None | -- | Neutral | 100 |
| psychiatric and dermatological management | -- | Neutral | 1 |
推奨摂取タイミング： With meals containing fat for optimal absorption; split doses if over 1,000 mg
Safety & Side Effects
報告されている副作用
- ⚠ Fishy aftertaste or burping
- ⚠ Mild gastrointestinal upset (nausea, diarrhea)
- ⚠ Possible increased bleeding time at high doses
- ⚠ Unpleasant body odor at very high doses
既知の相互作用
- ● Anticoagulants (warfarin) and antiplatelet drugs (may increase bleeding risk)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (reduces omega-3 absorption)
耐容上限摂取量： 3,000 mg/day EPA+DHA
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does オメガ3脂肪酸 help with 休止期脱毛症?
Based on 11 studies with 317 participants, there is moderate evidence from clinical studies that オメガ3脂肪酸 may support 休止期脱毛症 management. Our evidence grade is B (Good Evidence).
How much オメガ3脂肪酸 should I take for 休止期脱毛症?
Studies have used various dosages. A commonly studied range is 250-500 mg EPA+DHA/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of オメガ3脂肪酸?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal upset (nausea, diarrhea), Possible increased bleeding time at high doses, Unpleasant body odor at very high doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for オメガ3脂肪酸 and 休止期脱毛症?
We rate the evidence as Grade B (Good Evidence). This rating is based on 11 peer-reviewed studies with 317 total participants. The overall direction of effect is positive.
Related Evidence
オメガ3脂肪酸 他の症状・状態について
References
- [1] Michael M Ong et al.. Am J Clin Dermatol. 2026. Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations. doi:10.1007/s40257-025-00990-4 PubMed
- [2] Sarah Schaffer et al.. Cureus. 2025. A Scoping Review of Exosome Delivery Applications in Hair Loss. doi:10.7759/cureus.81152 PubMed
- [3] Azhar Ahmed et al.. Skin Appendage Disord. 2025. Herbal Remedies for Hair Loss: A Review of Efficacy and Safety. doi:10.1159/000542876 PubMed
- [4] Robert J Vanaria et al.. J Cosmet Dermatol. 2025. The Use of Light-Based Therapies in the Treatment of Alopecia. doi:10.1111/jocd.70434 PubMed
- [5] Boutros Soutou et al.. Indian J Dermatol. 2024. Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study. doi:10.4103/ijd.ijd_744_22 PubMed
- [6] S Cedirian et al.. J Cosmet Dermatol. 2023. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic … doi:10.1111/jocd.15873 PubMed
- [7] Kabir Sardana et al.. J Cosmet Dermatol. 2022. Role of nutritional supplements in selected dermatological disorders: A review. doi:10.1111/jocd.14436 PubMed
- [8] Kavita Poonia et al.. J Cosmet Dermatol. 2019. NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. doi:10.1111/jocd.12559 PubMed
- [9] Jana Zímová et al.. Acta Dermatovenerol Croat. 2016. Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl. PubMed
- [10] N V Tsiskarishvili et al.. Georgian Med News. 2007. [Effectiveness of the treatment plan for androgenetic alopecia]. PubMed
- [11] R M Trüeb. Ther Umsch. 2002. [Diffuse hair loss in women]. doi:10.1024/0040-5930.59.5.217 PubMed
- [12] D H Rushton. Dermatol Clin. 1993. Management of hair loss in women. PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。